|
(b)(4).A manufacturing record evaluation was performed for the finished device batch number plr214, and no non-conformances were identified.To date the device has not been returned.If the device or further details are received at a later date a supplemental medwatch will be sent.Additional information was requested and the following information was obtained: additional event information received on (b)(6) 2020 from no patient consequence.The surgeon had to take over stitches from the supra-dermal overjet which had become uncertain because it is a supra-dermal overjet made by ethilon 5-0.The device was discarded.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|
|
(b)(4).Date sent to the fda: 2/12/2021.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Additional h3 investigation summary: five pictures were received for evaluation.Upon visual inspection of the pictures, an empty labeled winding former, a overwrap packet an opened box and a detached needle of product code f2413h, lot # plr214 could be observed.As part of our quality process, the manufacturing records of this lot-serial number were reviewed, and the manufacturing standards were met prior to the release of this batch.No conclusion could be reached as on what caused the reported complaint, since the sample was not returned for analysis.Complaint information will be included in complaint trending that is reviewed on a regular basis to determine if further action is necessary.
|